SCHEMBL2633151

SCHEMBL2633151

Cc1nccn1CCC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 3/20 0.46
POLB P06746 1/20 0.46
FDPS P14324 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HTT P42858 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
TSHR P16473 1/20 0.40
ESR1 P03372 1/20 0.39
ALPL P05186 2/20 0.39
ALPG P10696 2/20 0.39
ALPI P09923 1/20 0.39
PLAA Q9Y263 1/20 0.39
GFER P55789 1/20 0.38
FPR2 P25090 1/20 0.38
NOS1 P29475 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15335292 0.84 ALPL (0.47) KMT2AALDH1A1POLBFDPSSMN1; SMN2
SCHEMBL2962697 0.83 KMT2A (0.57) KMT2AALDH1A1POLBFDPSSMN1; SMN2
SCHEMBL2970107 0.81 ALDH1A1 (0.53) KMT2AALDH1A1POLBSMN1; SMN2KDM4E
SCHEMBL2627811 0.81 SMN1; SMN2 (0.63) SMN1; SMN2TSHRESR1FPR2
SCHEMBL4235144 0.81 SMN1; SMN2 (0.37) KMT2AALDH1A1SMN1; SMN2KDM4EESR1
SCHEMBL22588365 0.78 KMT2A (0.44) KMT2AALDH1A1POLBFDPSHTT
SCHEMBL17916298 0.78 ALDH1A1 (0.49) KMT2AALDH1A1POLBFDPSSMN1; SMN2
SCHEMBL18510088 0.78 ALDH1A1 (0.49) KMT2AALDH1A1POLBFDPSSMN1; SMN2
SCHEMBL5707866 0.78 KMT2A (0.49) KMT2AALDH1A1POLBFDPSSMN1; SMN2
SCHEMBL992745 0.77 SMN1; SMN2 (0.61) KMT2AALDH1A1POLBFDPSSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921555-B2 Substituted-1,3,8-triazaspiro[4.5]decane-2,4-diones MERCK SHARP & DOHME CORP. (US) 2014-12-30 US disclosed
US-20120095001-A1 SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES MERCK SHARP & DOHME CORP. (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095001-A1 SUBSTITUTED-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES HIF1AN, HIF1A, EGLN2 KMT2A 208/4885ALDH1A1 156/4885POLB 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.